德琪医药有限公司（06996）于2026年2月4日发布截至2026年1月31日的股份变动月报表。公告显示，公司注册股本继续保持在2,000,000,000股，每股面值0.0001美元，总额200,000美元，较上月无变化。
已发行股份方面，截至报告期末，公司普通股合计679,244,132股，另有202,500股为库藏股，总数维持在679,446,632股，与上月持平，未发生新增发行、购回或注销。公司确认其公众持股量符合香港联交所相关上市规则的最低要求。
期权与激励计划方面，2020年股权激励计划当月有部分股权激励失效，合计减少期权155,500份；2022年受限制股份单位计划内有18,250股限制性股票单元失效。截至1月底，这些变动均未导致当月新增股份或库藏股转让，期末可因行使期权或归属股份激励而可能发行的股份总数为55,926,007股。
总体来看，德琪医药于2026年1月仍保持股本稳定，已发行股份及库藏股数量与上月一致。公告由公司主席梅建明博士签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.